Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID‐19 patients: A systematic review and meta‐analysis
J Peng, M Fu, H Mei, H Zheng, G Liang… - Reviews in medical …, 2022 - Wiley Online Library
As the pandemic progresses, the pathophysiology of coronavirus disease 2019 (COVID‐19)
is becoming clearer and the potential for immunotherapy is increasing. However, clinical …
is becoming clearer and the potential for immunotherapy is increasing. However, clinical …
Drug-induced liver injury in COVID-19 patients: a systematic review
F Sodeifian, ZS Seyedalhosseini, N Kian… - Frontiers in …, 2021 - frontiersin.org
Introduction: The severity of COVID-19 may be correlated with the risk of liver injury
development. An increasing number of studies indicate that degrees of hepatotoxicity has …
development. An increasing number of studies indicate that degrees of hepatotoxicity has …
A comprehensive review on the efficacy of several pharmacologic agents for the treatment of COVID-19
Simple Summary Treatments for coronavirus disease-2019 (COVID-19) have utilized a
variety of medications, including antivirals, immunomodulators, and other therapeutics such …
variety of medications, including antivirals, immunomodulators, and other therapeutics such …
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells for COVID-19 pneumonia: a meta-analysis of randomized controlled trials
Q Liu, F Ma, Y Zhong, G Wang, L Hu, Y Zhang… - Stem Cell Research & …, 2023 - Springer
Background Elevated levels of inflammatory factors are associated with poor prognosis in
coronavirus disease-19 (COVID-19). However, mesenchymal stem cells (MSCs) have …
coronavirus disease-19 (COVID-19). However, mesenchymal stem cells (MSCs) have …
Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes
J Sabbatinelli, G Matacchione, A Giuliani… - Mechanisms of Ageing …, 2022 - Elsevier
The COVID-19 pandemic caused by SARS-CoV-2 infection has been of unprecedented
clinical and socio-economic worldwide relevance. The case fatality rate for COVID-19 grows …
clinical and socio-economic worldwide relevance. The case fatality rate for COVID-19 grows …
Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
This study investigated the efficacy and safety of interleukin-6 (IL-6) receptor antagonists
with standard care treatment in patients with coronavirus disease 2019 (COVID-19). The …
with standard care treatment in patients with coronavirus disease 2019 (COVID-19). The …
Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: a systematic review and meta-analysis
L Luo, T Luo, M Du, H Mei, Y Hu - Journal of Infection, 2022 - journalofinfection.com
Fowler et al. 1 proposed RNA RT-LAMP as a rapid and accurate tool to promptly identify
highly contagious individuals during the pandemic era. In the current vaccination era, it …
highly contagious individuals during the pandemic era. In the current vaccination era, it …
Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials
F Ghaempanah, M Nikouei, M Cheraghi… - … Policy and Practice, 2023 - Taylor & Francis
Background This meta-analysis was conducted to investigate the impact of tocilizumab on
clinical outcomes associated with COVID-19. Methods A comprehensive search was …
clinical outcomes associated with COVID-19. Methods A comprehensive search was …
[HTML][HTML] Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID‐19 Pneumonia: A Single‐Center Retrospective Study
Objectives This study aimed to assess if tocilizumab (TCZ) timing is associated with
improved survival. Material and methods Data obtained from adult patients with …
improved survival. Material and methods Data obtained from adult patients with …
Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse …
Background: The in-hospital treatment for COVID-19 may include medicines from various
therapeutic classes, such as antiviral remdesivir and immunosuppressant tocilizumab …
therapeutic classes, such as antiviral remdesivir and immunosuppressant tocilizumab …